The net result: retatrutide's triple mechanism produces more GI disruption than either GLP-1 alone (semaglutide) or GLP-1 plus GIP (tirzepatide)
Singh, G., Krauthamer, M., & Bjalme-Evans, M
LSM changes in Appetite VAS and Eating Inventory from baseline with retatrutide were compared to those with placebo and dulaglutide at Weeks 4, 8, 12, 16, 24, and 36, and Weeks 24 and 36, respectively
How to transition safely between semaglutide and tirzepatide Whether you are alternating intentionally or switching due to circumstances, the transition process matters enormously
When the Tylenol Autism MDL was created in September 2022, 80 cases were consolidated across the nation
Food Addiction and Binge Eating Disorder GLP-1s suppress the appetite